Study study type PathologyT1T0Patientssample sizesROB Results

la/mBC - HR-positive - 1st line (L1) breast cancer - HR positive la/mBC - HR positive la/mBC - HR-positive - 1st line (L1)

versus letrozole
ribociclib plus letrozole
MONALEESA-2, 2016
  NCT01958021
RCTla/mBC - HR-positive - 1st line (L1)ribociclib plus letrozoleplacebo plus letrozolePostmenauposal women with locally confirmed HR-positive, HER2-negative recurrent or metastatic BC who had not received previous systematic therapy for advanced disease334 / 334low
conclusif
  • demonstrated 24 % decrease in deaths (OS) (PE)
  • demonstrated 44 % decrease in progression or deaths (PFS) (PE)